MEDBOT-B (02252) rose more than 6% again. At the time of writing, the stock was up 6.4%, trading at HK$32.24 with a turnover of HK$267 million. The surgical robotics sector has recently seen a series of positive developments, with continued policy support. Measures released by the Beijing Medical Insurance Bureau and other departments propose promoting the adoption of surgical robots in hospitals. Additionally, the Hunan Medical Insurance Bureau recently clarified the pricing standards for surgical robots and related auxiliary procedures. Industry experts believe surgical robots offer significant clinical benefits, and their global penetration rate is expected to keep rising. A UBS research report noted that the company's overseas revenue surged 287% year-over-year last year, with sales of its "Toumai" surgical robot increasing more than fivefold. The report indicated that MEDBOT-B aims to double its total revenue in 2026 compared to 2025 and expects the proportion of overseas revenue to rise from 73% last year to over 80%, potentially helping the company achieve breakeven in the first half of 2026.